Compile Data Set for Download or QSAR
Report error Found 35 Enz. Inhib. hit(s) with all data for entry = 1783
TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339961(US9758505, 34 | 5-(6-fluoro-1H-indol-3-yl)-N- meth...)
Affinity DataIC50: 290nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339928(US9758505, 1 | 6-fluoro-3-(6-methylpyridin-3- yl)-...)
Affinity DataIC50: 370nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339940(US9758505, 7 | 5-(6-fluoro-1H-indol-3-yl)- N,N-dim...)
Affinity DataIC50: 380nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339957(US9758505, 27 | 2-((5-(6-fluoro-1H-indol-3- yl)pyr...)
Affinity DataIC50: 490nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339955(US9758505, 25 | N1-(5-(6-fluoro-1H-indol-3- yl)pyr...)
Affinity DataIC50: 540nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339941(US9758505, 9 | 4-(5-(6-fluoro-1H-indol-3- yl)pyrid...)
Affinity DataIC50: 540nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339929(US9758505, 2 | 6-fluoro-3-(6-(piperidin-4- yloxy)p...)
Affinity DataIC50: 560nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339953(US9758505, 21 | N-(3-((5-(6-fluoro-1H-indol-3- yl)...)
Affinity DataIC50: 620nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339950(US9758505, 19 | 5-(6-fluoro-1H-indol-3-yl)-N- (1-(...)
Affinity DataIC50: 650nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339943(US9758505, 11 | 2-amino-1-(4-(5-(6-fluoro-1H- indo...)
Affinity DataIC50: 650nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339956(US9758505, 26 | N-(2-((5-(6-fluoro-1H-indol-3- yl)...)
Affinity DataIC50: 710nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339942(US9758505, 10 | 6-fluoro-3-(6-(4- methylpiperazin-...)
Affinity DataIC50: 720nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339938(US9758505, 5 | 6-fluoro-3-(6-methoxypyridin- 3-yl)...)
Affinity DataIC50: 730nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339960(US9758505, 31 | 2-((5-(6-fluoro-1H-indol-3- yl)pyr...)
Affinity DataIC50: 790nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339963(US9758505, 44 | 6-fluoro-3-(pyridin-3-yl)-1H- indo...)
Affinity DataIC50: 850nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339964(US9758505, 45 | 6-fluoro-3-(2-methylpyridin-3- yl)...)
Affinity DataIC50: 860nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339951(US9758505, 20 | N-(3-((5-(6-fluoro-1H-indol-3- yl)...)
Affinity DataIC50: 870nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339948(US9758505, 17 | 5-(6-fluoro-1H-indol-3-yl)-N- (pip...)
Affinity DataIC50: 870nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339945(US9758505, 14 | N-(1-(5-(6-fluoro-1H-indol-3- yl)p...)
Affinity DataIC50: 970nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339962(US9758505, 40 | N-(5-(6-fluoro-1H-indol-3- yl)pyri...)
Affinity DataIC50: 1.00E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339946(US9758505, 15 | 5-(6-fluoro-1H-indol-3- yl)pyridin...)
Affinity DataIC50: 1.10E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339954(US9758505, 22 | 5-(6-fluoro-1H-indol-3-yl)-N- (3-(...)
Affinity DataIC50: 1.20E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339936(US9758505, 3 | 6-fluoro-3-(6-((1- methylpiperidin-...)
Affinity DataIC50: 1.20E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339939(US9758505, 6 | 5-(6-fluoro-1H-indol-3-yl)-N- (1-(m...)
Affinity DataIC50: 1.30E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339958(US9758505, 28 | 5-(6-fluoro-1H-indol-3-yl)-N- (2-(...)
Affinity DataIC50: 1.50E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339959(US9758505, 30 | 2-((5-(6-fluoro-1H-indol-3- yl)pyr...)
Affinity DataIC50: 1.60E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339947(US9758505, 16 | 5-(5,6-difluoro-1H-indol-3- yl)pyr...)
Affinity DataIC50: 1.60E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339944(US9758505, 13 | 2-amino-N-(1-(5-(6-fluoro- 1H-indo...)
Affinity DataIC50: 1.70E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339966(US9758505, 47 | 5,6-difluoro-3-(pyridin-3-yl)- 1H-...)
Affinity DataIC50: 2.80E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339967(US9758505, 48 | 6-fluoro-3-(5-methylpyridin-3- yl)...)
Affinity DataIC50: 4.50E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339949(US9758505, 18 | N-(1-ethylpiperidin-4-yl)-5-(6- fl...)
Affinity DataIC50: 4.80E+3nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339968(US9758505, 49 | 3-(6-fluoro-1H-indol-3- yl)pyridin...)
Affinity DataIC50: 1.10E+4nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339965(US9758505, 46 | 6-fluoro-3-(4-methylpyridin-3- yl)...)
Affinity DataIC50: 1.30E+4nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339969(US9758505, 78 | 1-(5-(6-fluoro-1H-indol-3- yl)pyri...)
Affinity DataIC50: 1.60E+4nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iteos Therapeutics

US Patent
LigandPNGBDBM339937(US9758505, 4 | 2-((5-(6-fluoro-1H-indol-3- yl)pyri...)
Affinity DataIC50: 3.90E+4nMAssay Description:The compounds of formula I inhibit the enzymatic activity of human TDO2.To measure the TDO2 activity, the procedure described in Dolusic et al. J. Me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
Go to US Patent